Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;4(2):39-43.
doi: 10.2217/hep-2016-0011. Epub 2017 Sep 8.

Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib

Petros Giovanis  1   1 , Graziano Pianezze  2   2 , Valter Vincenzi  3   3 , Carla Manuppelli  3   3 , Massimo Boaretto  3   3 , Davide Pastorelli  1   1
Affiliations
Review

Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib

Petros Giovanis et al. Hepat Oncol. 2017 Apr.

Abstract

Aim: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP).

Materials & methods: CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks.

Results: Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1-6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months.

Conclusion: Treatment with sorafenib changed CEC levels in HCC patients.

Keywords: CECs; angiogenesis inhibitors; hepatocellular carcinoma; sorafenib.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Circulating endothelial cells and HPCs modulation.
Black and white will be fine.
See this image and copyright information in PMC

References

    1. Reyers M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 2002;109:337–346. - PMC - PubMed
    1. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003;9:702–712. - PubMed
    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350(23):2335–2342. - PubMed
    1. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 2008;26:127–131. - PubMed
    1. Bruix J, Sherman M. Practice guidelines committee, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236. - PubMed

LinkOut - more resources